Pulse Biosciences stock has delivered a very strong share price run, yet the current valuation checks lean expensive rather than cheap. After a 3 year return that stands far above a typical single digit gain, the stock now sits on a low overall value score and screens as overvalued on market multiples.

• Pulse Biosciences has returned 315.1% over the past 3 years, which places a lot of expectation on the business to justify that kind of share price performance over time.
• The key support for the valuation can come from the company eventually translating its technology and pipeline into consistent revenue growth. The main risk is that cash needs or slower commercial progress lead investors to reassess how much they are willing to pay today.
• The stock currently passes 0 of 6 valuation checks on Simply Wall St, which suggests it is not a clear bargain on broader metrics such as multiples and balance sheet strength see the full valuation summary here.

The issue now is whether the recent share price performance in Pulse Biosciences leaves enough valuation support for new investors coming in at current levels.

Has Pulse Biosciences Run Too Far on Book Value?

P/B is often useful for early stage medical equipment companies like Pulse Biosciences because tangible equity can give a simple anchor when earnings and cash flows are still volatile. It helps you see how much you are paying relative to the company’s net assets.

Pulse Biosciences currently trades at a P/B of 34.2x, compared with about 2.4x for the wider Medical Equipment industry and 7.1x for peers in its valuation peer set. That is a very large premium to both benchmarks. The internal model here also flags an extreme gap, since it heavily penalises the company’s current losses and risk profile, and treats this level of P/B as a warning signal rather than something close to a modelled fair value.

At this price, the market is asking investors to pay far more for each dollar of book value in Pulse Biosciences than is typical for the sector or its peer group. This leaves little room for disappointment if progress is slower than hoped.

On the P/B multiple alone, Pulse Biosciences stock screens as clearly overvalued relative to both its industry and peer benchmarks.

The Pulse Biosciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Pulse Biosciences sit between the high P/B ratio you just saw and the real world progress the business needs to make. They spell out the specific assumptions on growth, margins and earnings that would need to hold for Pulse Biosciences' stock to be worth materially more or less than today's price. They also turn a single output from a ratio or model into a forward path you can monitor over time on the Community page.

One of the top community narratives on Pulse Biosciences: 7% overvalued

"Bullish analysts highlight Pulse Biosciences' differentiated cardiac ablation platform as a key asset that could support the current fair value estimate near US$30.67 per share…"

Do you think there's more to the story for Pulse Biosciences? Head over to our Community to see what others are saying!

The Bottom Line

Pulse Biosciences now trades on market multiples that screen as clearly overvalued, with an extreme gap to both industry and peer benchmarks. The broader valuation checks are weak, which means you are paying up despite ongoing losses and execution risk. From here, the key question is whether Pulse Biosciences can turn its technology into sustained commercial adoption quickly enough to support this premium, or whether the multiple has simply run ahead of what the business can reasonably deliver.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.